市場調查報告書

短腸症候群市場(各類藥物:類升糖素肽2(GLP-2),生長激素,麩醯胺酸,其他) - 全球產業分析,規模,佔有率,成長,趨勢,預測

Short Bowel Syndrome Market (Drug Class: Glucagon-like Peptide-2 (GLP-2), Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 926750
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
短腸症候群市場(各類藥物:類升糖素肽2(GLP-2),生長激素,麩醯胺酸,其他) - 全球產業分析,規模,佔有率,成長,趨勢,預測 Short Bowel Syndrome Market (Drug Class: Glucagon-like Peptide-2 (GLP-2), Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2020年01月20日內容資訊: 英文 176 Pages
簡介

本報告提供全球短腸症候群市場相關調查,彙整市場趨勢與預測,市場規模,主要加入企業,各地區趨勢相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 各類型概要
  • 產業趨勢
  • 市場趨勢
  • 促進因素與阻礙因素概要分析
  • 促進要素
  • 阻礙要素
  • 機會
  • 市場收益預測

第5章 主要洞察

  • 促進因素與阻礙因素的影響分析
  • 價值鏈分析
  • 短腸症候群:疾病概要
  • 短腸症候群:流行病學
  • 罕見疾病罹患率
  • 短腸症候群臨床實驗概要
  • GLP-2產品的定性分析
  • 研究開發成本分析
  • 臨床試驗費用對孤兒藥的影響分析
  • 使用孤兒藥的治療成本分析 其他

第6章 市場分析:各類藥物

  • 簡介
  • 市場值與預測
    • 類升糖素肽2(GLP-2)
    • 生長激素
    • 麩醯胺酸
    • 其他
  • 市場分析
  • 市場魅力度分析

第7章 市場分析:各地區

  • 市場值與預測
  • 市場預測
    • 北美
    • 歐洲
    • 日本
    • 其他
  • 市場分析
  • 市場魅力度分析

第8章 北美

第9章 歐洲

第10章 日本

第11章 其他各國

第12章 競爭環境

  • 企業簡介
目錄
Product Code: TMRGL13346

Short Bowel Syndrome Market - Scope of the Report

TMR's report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global short bowel syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the short bowel syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983-2015, approved European orphan indications, 2019, pricing analysis, orphan drugs - price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

The report analyzes the short bowel syndrome market in terms of drug class and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the short bowel syndrome market.

Key Questions Answered in Short Bowel Syndrome Market Report

What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?

What are the major drivers, restraints, and opportunities in the market?

Which region is set to expand at the fastest CAGR during the forecast period?

Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?

Short Bowel Syndrome Market - Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Key players operating in the short bowel syndrome market include Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, and Naia Pharmaceuticals, Inc.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Short Bowel Syndrome Market: Market Snapshot

4. Market Overview

  • 4.1. Global Short Bowel Syndrome Market: Type Overview
  • 4.2. Global Short Bowel Syndrome Market: Key Industry Developments
  • 4.3. Market Dynamics
  • 4.4. Drivers and Restraints Snapshot Analysis
  • 4.5. Drivers
    • 4.5.1. High cost of parenteral nutrition increases demand for SBS drugs
    • 4.5.2. Favorable reimbursement scenario
  • 4.6. Restraints
    • 4.6.1. Side effects associated with SBS drugs
    • 4.6.2. Non-availability of approved drugs globally
  • 4.7. Opportunities
  • 4.8. Global Short Bowel Syndrome Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights

  • 5.1. Drivers & Restraints Impact Analysis
  • 5.2. Value Chain Analysis
  • 5.3. Short Bowel Syndrome: Disease Overview
  • 5.4. Short Bowel Syndrome: Epidemiology
  • 5.5. Rare Diseases Prevalence
  • 5.6. Overview of Clinical Trials for Short Bowel Syndrome
  • 5.7. Qualitative Analysis of GLP-2 Product
  • 5.8. Research & Development Cost Analysis
  • 5.9. Impact Analysis of Clinical Trials Cost on Orphan Drugs
  • 5.10. Cost Analysis of Therapies using Orphan Drugs
  • 5.11. Approved U.S. Orphan Indications, 1983-2015
  • 5.12. Approved European Orphan Indications, 2019
  • 5.13. Pricing Analysis
  • 5.14. Orphan Drugs - Price Volume Analysis
  • 5.15. Justifications for the High Cost of Gattex & Teduglutide
  • 5.16. Regulations Scenario Assessment
  • 5.17. Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia
  • 5.18. Impact Analysis of Regulatory Scenario Assessment
  • 5.19. Comparative Analysis of Orphan Drug Policies
  • 5.20. Orphan Drug Manufacturing Companies - Acquisitions Timeline
  • 5.21. Orphan Drugs Market- SWOT Analysis

6. Global Short Bowel Syndrome Market Analysis, by Drug Class

  • 6.1. Introduction
  • 6.2. Global Short Bowel Syndrome Market Value and Forecast, by Drug Class
    • 6.2.1. Glucagon-like Peptide-2 (GLP-2)
    • 6.2.2. Growth Hormone
    • 6.2.3. Glutamine
    • 6.2.4. Others
  • 6.3. Global Short Bowel Syndrome Market Analysis, by Drug Class
  • 6.4. Global Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

7. Global Short Bowel Syndrome Market Analysis, by Region

  • 7.1. Global Short Bowel Syndrome Market Value and Forecast, by Region, 2017-2027
    • 7.1.1. North America
    • 7.1.2. Europe
    • 7.1.3. Japan
    • 7.1.4. Rest of the World
  • 7.2. Global Short Bowel Syndrome Market Analysis, by Region
  • 7.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region

8. North America Short Bowel Syndrome Market Analysis

  • 8.1. North America Short Bowel Syndrome Market
  • 8.2. North America Short Bowel Syndrome Market Overview
  • 8.3. North America Short Bowel Syndrome Market Value and Forecast, by Drug Class
    • 8.3.1. Glucagon-like Peptide-2 (GLP-2)
    • 8.3.2. Growth Hormone
    • 8.3.3. Glutamine
    • 8.3.4. Others
  • 8.4. North America Short Bowel Syndrome Market Forecast, by Country
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. North America Short Bowel Syndrome Market Attractiveness Analysis
    • 8.5.1. By Drug Class
    • 8.5.2. By Country

9. Europe Short Bowel Syndrome Market Analysis

  • 9.1. Europe Short Bowel Syndrome Market
  • 9.2. Europe Short Bowel Syndrome Market Overview
  • 9.3. Europe Short Bowel Syndrome Market Value and Forecast, by Drug Class
    • 9.3.1. Glucagon-like Peptide-2 (GLP-2)
    • 9.3.2. Growth Hormone
    • 9.3.3. Glutamine
    • 9.3.4. Others
  • 9.4. Europe Short Bowel Syndrome Market Forecast, by Country/Sub-region
    • 9.4.1. U.K.
    • 9.4.2. France
    • 9.4.3. Germany
    • 9.4.4. Spain
    • 9.4.5. Italy
    • 9.4.6. Rest of Europe
  • 9.5. Europe Short Bowel Syndrome Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Country/Sub-region

10. Japan Short Bowel Syndrome Market Analysis

  • 10.1. Japan Short Bowel Syndrome Market Key Findings
  • 10.2. Japan Short Bowel Syndrome Market Overview
  • 10.3. Japan Short Bowel Syndrome Market Value and Forecast, by Drug Class
    • 10.3.1. Glucagon-like Peptide-2 (GLP-2)
    • 10.3.2. Growth Hormone
    • 10.3.3. Glutamine
    • 10.3.4. Others
  • 10.4. Japan Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

11. Rest of the World Short Bowel Syndrome Market Analysis

  • 11.1. Rest of the World Short Bowel Syndrome Market Key Findings
  • 11.2. Rest of the World Short Bowel Syndrome Market Overview
  • 11.3. Rest of the World Short Bowel Syndrome Market Value and Forecast, by Drug Class
    • 11.3.1. Glucagon-like Peptide-2 (GLP-2)
    • 11.3.2. Growth Hormone
    • 11.3.3. Glutamine
    • 11.3.4. Others
  • 11.4. Rest of the World Short Bowel Syndrome Market Analysis, by Country/Sub-region
    • 11.4.1. China
    • 11.4.2. India
    • 11.4.3. Australia/New Zealand
    • 11.4.4. Middle East
    • 11.4.5. Brazil

12. Competitive Landscape

  • 12.1. Company Profiles
    • 12.1.1. Shire plc (Takeda Pharmaceutical Company Limited)
      • 12.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.1.2. Financials
      • 12.1.1.3. Recent Developments
      • 12.1.1.4. Strategy
    • 12.1.2. Zealand Pharma A/S
      • 12.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.2.2. Financials
      • 12.1.2.3. Recent Developments
      • 12.1.2.4. Strategy
    • 12.1.3. Sancilio & Company, Inc.
      • 12.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.3.2. Recent Developments
      • 12.1.3.3. Strategy
    • 12.1.4. OxThera
      • 12.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.4.2. Recent Developments
      • 12.1.4.3. Strategy
    • 12.1.5. Nutrinia Ltd
      • 12.1.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.5.2. Recent Developments
      • 12.1.5.3. Strategy
    • 12.1.6. Ardelyx, Inc.
      • 12.1.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.6.2. Financials
      • 12.1.6.3. Recent Developments
      • 12.1.6.4. Strategy
    • 12.1.7. Emmaus Life Sciences, Inc.
      • 12.1.7.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.7.2. Financials
      • 12.1.7.3. Recent Developments
      • 12.1.7.4. Strategy
    • 12.1.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)
      • 12.1.8.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.8.2. Financials
      • 12.1.8.3. Recent Developments
      • 12.1.8.4. Strategy
    • 12.1.9. Merck KGaA
      • 12.1.9.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.9.2. Financials
      • 12.1.9.3. Recent Developments
      • 12.1.9.4. Strategy
    • 12.1.10. Naia Pharmaceuticals, Inc.
      • 12.1.10.1. Overview (HQ, Employee Strength, Business Segments)
      • 12.1.10.2. Recent Developments
      • 12.1.10.3. Strategy

List of Tables

  • TABLE 1 Overview of Clinical Trials for Short Bowel Syndrome (1/2)
  • TABLE 2 Overview of Clinical Trials for Short Bowel Syndrome (2/2)
  • TABLE 3 Orphan Drugs Research & Development Cost (US$ Mn), 2014-2018
  • TABLE 4 Impact Analysis of Clinical Trials Cost on Orphan Drugs (1/2)
  • TABLE 5 Impact Analysis of Clinical Trials Cost on Orphan Drugs (2/2)
  • TABLE 6 Comparative Analysis of Orphan Drug Policies
  • TABLE 7 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 8 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Region, 2019-2027
  • TABLE 9 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 10 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • TABLE 11 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 12 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 13 Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

List of Figures

  • Figure 1: Market Size Estimation Methodology
  • Figure 2: Market Snapshot Global Short Bowel Syndrome Market
  • Figure 3: Global Short Bowel Syndrome Market Revenue (US$ Mn) (2018)
  • Figure 4: Global Short Bowel Syndrome Market Top 3 Trends
  • Figure 5: Global Short Bowel Syndrome Market Key Drivers, Restraints, and Trends
  • Figure 6: Global Short Bowel Syndrome Market Value (US$ Mn) and Distribution by Geography, 2018 and 2027
  • Figure 7: Drivers and Restraints Snapshot Analysis (1/2)
  • Figure 8: Drivers and Restraints Snapshot Analysis (2/2)
  • Figure 9: Opportunity Analysis Global Short Bowel Syndrome Market
  • Figure 10: Global Short Bowel Syndrome Market Value (US$ Mn) and Forecast, 2017-2027
  • Figure 11: Porter's Five Force Analysis Global Short Bowel Syndrome Market
  • Figure 12: Drivers Impact Analysis Short Bowel Syndrome (SBS) Market
  • Figure 13: Restraints Impact Analysis Short Bowel Syndrome (SBS) Market
  • Figure 14: Value Chain: Short Bowel Syndrome (SBS) Market (Gattex)
  • Figure 15: Pathophysiology Short Bowel Syndrome
  • Figure 16: Causes of SBS in Neonates in Neonatal Intensive Care Units (NICU)
  • Figure 17: Causes of SBS in Adults
  • Figure 18: Prevalence of Orphan (rare) Diseases
  • Figure 19: Amino Acid Sequence of Teduglutide (GLP-2)
  • Figure 20: Amino Acid Sequence of Natural GLP-2
  • Figure 21: Mode of Action of GLP-2 Product
  • Figure 22: Orphan Drugs Research & Development Cost (US$ Mn), 2014-2018
  • Figure 23: U.S. Average Cost of Therapies using Orphan Drugs per Patients (US$/Patients/Year)
  • Figure 24: Approved U.S. Orphan Indications, 1983-2015
  • Figure 25: Approved European Orphan Indications, 2019
  • Figure 26: Factors Contributing to Orphan Drugs Pricing Decision
  • Figure 27: Pricing of Certain Orphan Drugs (US$ per patient per year)
  • Figure 28: Factors for High Prices of Orphan Drugs
  • Figure 29: Orphan Drugs - Price Volume Analysis
  • Figure 30: Justifications for the High Cost of Gattex & Teduglutide
  • Figure 31: U.S. Regulatory Scenario Assessment Flow Chart
  • Figure 32: Regulatory Approval Process- Europe
  • Figure 33: Regulatory Approval Process- Japan
  • Figure 34: Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia (excluding financial viability and new dosage form medicines)
  • Figure 35: Impact Analysis of Regulatory Scenario Assessment
  • Figure 36: Orphan Drugs Market- SWOT Analysis
  • Figure 37: Introduction - Global Short Bowel Syndrome (SBS) Market, by Drug Class (2/2)
  • Figure 38: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 39: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glucagon-like Peptide-2 (GLP-2), 2017-2027
  • Figure 40: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Growth Hormone, 2017-2027
  • Figure 41: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glutamine, 2017-2027
  • Figure 42: Global Short Bowel Syndrome (SBS) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 43: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 44: Global Market Scenario
  • Figure 45: Introduction - Global Short Bowel Syndrome (SBS) Market: by Region (2/2)
  • Figure 46: Global Short Bowel Syndrome (SBS) Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 47: Global Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Region
  • Figure 48: North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 49: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 50: North America Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 51: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 52: North America Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 53: Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 54: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 55: Europe Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 56: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 57: Europe Short Bowel Syndrome (SBS) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 58: Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 59: Japan Short Bowel Syndrome (SBS) Market Attractiveness Analysis, by Drug Class
  • Figure 60: Japan Short Bowel Syndrome (SBS) Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 61: Rest of the World (excluding Japan) Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 62: Global Short Bowel Syndrome (SBS) Market Share Analysis, by Company (2018)
  • Figure 63: Shire plc Internal Medicine Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 64: Shire plc Breakdown of Net Sales (%), by Region/Country, 2017
  • Figure 65: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 66: Shire plc SWOT ANALYSIS
  • Figure 67: Zealand Pharma A/S Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 68: Zealand Pharma A/S SWOT ANALYSIS
  • Figure 69: Sancilio & Company, Inc. SWOT ANALYSIS
  • Figure 70: OxThera SWOT ANALYSIS
  • Figure 71: Nutrinia Ltd. SWOT ANALYSIS
  • Figure 72: Ardelyx, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2018
  • Figure 73: Ardelyx, Inc. Breakdown of Net Sales, by Revenue Type, 2018
  • Figure 74: Ardelyx, Inc. Research & Development Cost 2015 -2017
  • Figure 75: Ardelyx, Inc. SWOT ANALYSIS
  • Figure 76: Emmaus Life Sciences, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2018
  • Figure 77: Emmaus Life Sciences, Inc. R&D Spending and Sales & Marketing Expenses (US$ Mn), Company Level, 2017-2018
  • Figure 78: Emmaus Life Sciences, Inc. Breakdown of Net Sales, by Service Type, 2018
  • Figure 79: Emmaus Life Sciences, Inc. SWOT ANALYSIS
  • Figure 80: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • Figure 81: Pfizer Inc. Breakdown of Net Sales, by Region/Country, 2018
  • Figure 82: Pfizer Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • Figure 83: Pfizer Inc. Breakdown of Net Sales, by Business Segment (%), 2018
  • Figure 84: SWOT ANALYSIS (Pfizer Inc.)
  • Figure 85: Merck KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 86: Merck KGaA R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 87: Merck KGaA Breakdown of Net Sales (%), by Region, 2018
  • Figure 88: Merck KGaA Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 89: Merck KGaA SWOT ANALYSIS
  • Figure 90: Naia Pharmaceuticals, Inc. SWOT ANALYSIS